Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Starting soon · Phase 1

Conditions studied: Ovarian Cancer

In brief

Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215

Key facts

Study ID

NCT07532148

Run by

Chong Kun Dang Pharmaceutical

People needed

24

Starts

2026-06-01

Expected to finish

2027-08-01

Last updated by the study team

2026-04-15

Who can join

Age: 19 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Between 19 aged and 75 aged in patients with advanced BRCA-mutated high-grade epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
• 18.0kg/m2≤body mass index(BMI)≤28.0kg/m2

You may not qualify if…

• Have a gastrointestinal disease(Crohn's disease, ulcer etc.) history that can effect drug absorption or surgery
• Patients with central nervous system metastases, unless clinically stable after treatment
• CTCAE Grade 3 or higher adverse events(e.g., anemia, neutropenia, dysgeusia, cough, leukopenia, thrombocytopenia) related to D215
• Subjects who are unable to participate in this clinical trial at the discretion of the investigator

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.